Open an account

Phio Pharmaceuticals

PHIO · NASDAQ

$0.8921+$0.0232 (+2.67%)TodayMarket closed ·
Prev close $0.8689

About PHIO

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 6 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Employees
6
Headquarters
King of Prussia, Pennsylvania
Listed
May 10, 2012
Sector
Health Care
Industry
Biotechnology
Website
phiopharma.com

PHIO key statistics

Market cap
10.36M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
102.37K
Volume
60.65K
Open price
$0.87
High today
$0.9099
Low today
$0.859
52 Week high
$4.19
52 Week low
$0.8127

Phio Pharmaceuticals (PHIO) at a glance

As of Oct 20, 2026, Phio Pharmaceuticals (PHIO) shares are priced at $0.8921, giving the company a market cap of 10.36M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.859 and $0.9099. The current price is 3.9% above the day's low and 2.0% below its high.

Volume so far is 60.65K shares, below the average of 102.37K shares a day.

Over the past year Phio Pharmaceuticals has ranged from $0.8127 to $4.19, and now sits 2% of the way up that range.

Phio Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.36 per share against an estimate of -$0.3672.

The average analyst price target is $14.28, 1500.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $14.28
Low
$14.14
Now
$0.8921
High
$14.70

PHIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 25.3% on average.

  1. Q2 FY24: reported -$3.62 per share against an estimate of -$4.68
  2. Q3 FY24: reported -$1.54 per share against an estimate of -$4.22
  3. Q4 FY24: reported -$0.85 per share against an estimate of -$1.25
  4. Q2 FY25: reported -$0.45 per share against an estimate of -$0.3672
  5. Q3 FY25: reported -$0.44 per share against an estimate of -$0.459
  6. Q4 FY25: reported -$0.253 per share against an estimate of -$0.3468
  7. Q1 FY26: reported -$0.34 per share against an estimate of -$0.2397
  8. Q2 FY26: reported -$0.36 per share against an estimate of -$0.3672

PHIO news

  • Press releaseNewsfile

    Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseNewsfile

    Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

  • Press releaseNewsfile

    Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

  • Vandana Singh

    What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?

  • Alex Perry

    Why Is Phio Pharmaceuticals Stock Soaring Today?

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releaseNewsfile

    Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as Phio Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.